Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BSH 2018 | Future improvements in developing CLL therapy

Peter Hillmen • 6 Apr 2018
BSH 2018
Chronic Lymphocytic Leukemia Leukemia

While the treatment landscape of chronic lymphocytic lymphoma (CLL) has been exciting with many breakthrough therapies, there are still key areas for improvement. Speaking from the British Society for Haematology (BSH) 2018 Annual Meeting in Liverpool, UK, Peter Hillmen, MBChB, PhD, FRCP, FRCPath, from the University of Leeds and Leeds Teaching Hospitals NHS Trust, Leeds, UK stresses the importance of moving novel therapies rapidly into Phase III trials if they have shown promising results. Prof. Hillmen also talks about banking samples and translational research to improve understanding and refine treatment.

More from Peter Hillmen

1:55
Key updates from the interim analysis of the FLAIR trial
Peter Hillmen • 10 Jun 2022
1:03
CLL trial updates from EHA 2022
Peter Hillmen • 10 Jun 2022
1:19
Acalabrutinib vs ibrutinib in previously untreated high-risk CLL
Peter Hillmen • 10 Jun 2022
1:40
The role of MRD in decision-making in CLL
Peter Hillmen • 10 Jun 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals